ArticleCancer gene therapy2026
LncRNA PCAT7 drives tumorigenesis and glycolytic reprogramming in breast cancer via the ceRNA-mediated miR-204-5p/RUNX2 axis.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BRCA) development is tightly linked to metabolic dysregulation, with enhanced aerobic glycolysis standing out as a key hallmark, and competing endogenous RNA (ceRNA) mechanisms have emerged as critical epigenetic regulators of tumor metabolic pathways-this study thus aimed to explore glycolytic regulation through ceRNA networks in BRCA, with the goal of identifying potential prognostic biomarkers and mechanistic targets. To achieve this, we integrated comprehensive bioinformatics analyses of The Cancer Genome Atlas (TCGA) dataset with experimental validation to identify PCAT7 as a functionally relevant long non-coding RNA (lncRNA), complemented by functional assays including cell proliferation tests, glucose consumption measurements, and lactate production assays, as well as molecular interaction verification using luciferase reporter assays and RNA immunoprecipitation (RIP). Our results showed that PCAT7 is overexpressed in BRCA tissues and correlates with poor patient prognosis; mechanistically, PCAT7 acts as a molecular sponge for miR-204-5p, alleviating its inhibitory effect on RUNX2 and thereby regulating key glycolytic regulators including GLUT1 and PKM2, while silencing PCAT7 suppresses tumor cell proliferation, invasion, migration, and glycolytic activity in vitro. Collectively, this study uncovers a novel ceRNA network involving PCAT7/miR-204-5p/RUNX2 that drives glycolytic metabolism in BRCA, advancing our understanding of epigenetic regulation in cancer metabolism and highlighting PCAT7 as a potential prognostic biomarker for BRCA patients, with future in vivo studies needed to further validate the therapeutic potential of targeting this axis. Created in https://BioRender.com .
Indexed as
Identifiers
42576052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.